绿康生化(002868) - 2022 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2022 was ¥62,687,107.78, a decrease of 31.06% compared to ¥90,930,335.34 in the same period last year[2] - The net profit attributable to shareholders was a loss of ¥8,913,785.79, representing a decline of 471.12% from a profit of ¥2,401,830.67 in Q1 2021[2] - The company's basic and diluted earnings per share were both -¥0.06, a decrease of 400.00% compared to ¥0.02 in Q1 2021[2] - Net loss for Q1 2022 was ¥9,003,935.49, compared to a net profit of ¥2,294,256.78 in Q1 2021, indicating a significant decline in profitability[27] - The company's operating profit for Q1 2022 was -¥11,082,787.91, contrasting with an operating profit of ¥1,509,334.75 in the previous year[27] Cash Flow - The net cash flow from operating activities improved to ¥5,001,432.08, a 120.00% increase from a negative cash flow of ¥25,012,216.19 in the previous year[2] - Cash received from tax refunds was ¥23,801,853.00, a 407.92% increase from ¥4,686,184.98 in Q1 2021, primarily due to cumulative VAT refunds[8] - Total cash inflow from financing activities was ¥78,065,760.00, up from ¥37,919,160.40 in the same period last year[32] - The net cash flow from investing activities was -¥57,605,711.99, compared to -¥73,736,543.37 in Q1 2021, indicating a reduced cash outflow[31] - The company reported cash inflow from operating activities totaling ¥108,143,832.33, compared to ¥72,131,062.74 in Q1 2021, reflecting a year-over-year increase of approximately 50%[31] Assets and Liabilities - Total assets at the end of Q1 2022 were ¥1,233,272,816.55, down 2.00% from ¥1,258,398,896.70 at the end of the previous year[2] - The company's total liabilities increased, with contract liabilities rising by 158.25% to ¥2,362,258.12 due to an increase in advance payments received[6] - The total liabilities as of the end of Q1 2022 were ¥520,254,732.54, a decrease from ¥536,376,689.72 at the end of the previous year[24] - The total equity attributable to shareholders of the parent company was ¥708,713,213.14, down from ¥717,626,998.92 in the previous year[24] Shareholder Information - Total number of common shareholders at the end of the reporting period is 9,688[11] - Shanghai Kangyi Investment Co., Ltd. holds 30.43% of shares, totaling 47,291,400 shares, with 9,378,390 shares pledged[11] - Helix (Asia) Investment Co., Ltd. holds 26.70% of shares, totaling 41,489,860 shares[11] - The top ten shareholders include both domestic and foreign entities, with significant stakes held by non-state-owned legal persons[11] Government Subsidies and Investments - The company received government subsidies amounting to ¥1,082,490.80 during the quarter, which are closely related to its normal business operations[4] - The company plans to raise up to 305 million RMB through a non-public offering of up to 46,624,751 shares[13] - The project for producing 1,200 tons of active bacterial peptide premix and 1,200 tons of veterinary raw materials (sulfamethoxazole) was delayed and completed by March 31, 2022, with additional self-funded investment of up to RMB 80 million approved[17] - The total investment for the cogeneration project in the Pucheng Putan Industrial Park is approximately RMB 201.17 million, aimed at ensuring stable heating quality and reducing electricity costs[20] Operational Efficiency - The company plans to continue expanding its production capacity and improve operational efficiency through strategic investments and project completions[20] - Research and development expenses for Q1 2022 amounted to ¥5,785,241.05, slightly down from ¥6,280,220.20 in Q1 2021[27] - The company's fixed assets increased significantly to RMB 662.08 million from RMB 198.08 million year-on-year[23] Miscellaneous - The report for Q1 2022 was not audited, indicating that the figures may be subject to change upon final review[33]